Cargando…

Improvement initiative in LDL-C management in Saudi Arabia: A call to action()

PURPOSE: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the Saudi Arabia (KSA). Over the last decade dyslipidemia has been the predominant risk factor in KSA. The linear relationship between low density lipoprotein cholesterol (LDL-C) levels, a marker for dyslipidemi...

Descripción completa

Detalles Bibliográficos
Autores principales: Alasnag, Mirvat, Awan, Zuhier, Al Ghamdi, Ahmed, Al Modaimeigh, Hind, Al Shemiri, Mostafa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596183/
https://www.ncbi.nlm.nih.gov/pubmed/33145395
http://dx.doi.org/10.1016/j.ijcha.2020.100667
_version_ 1783602048691863552
author Alasnag, Mirvat
Awan, Zuhier
Al Ghamdi, Ahmed
Al Modaimeigh, Hind
Al Shemiri, Mostafa
author_facet Alasnag, Mirvat
Awan, Zuhier
Al Ghamdi, Ahmed
Al Modaimeigh, Hind
Al Shemiri, Mostafa
author_sort Alasnag, Mirvat
collection PubMed
description PURPOSE: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the Saudi Arabia (KSA). Over the last decade dyslipidemia has been the predominant risk factor in KSA. The linear relationship between low density lipoprotein cholesterol (LDL-C) levels, a marker for dyslipidemia, and progression of ASCVD is well established. The objective of this paper is to to provide an overview of the burden of disease, outline current clinical practice guidelines (CPG), examine gaps in care, and provide actionable recommendations to prevent, diagnose, and treat dyslipidemia in KSA. RESULTS: Saudi Arabia has the highest prevalence of ASCVD in the Gulf region. Several gaps in the implementation of CPGs, including the underdiagnosis and undertreatment of dyslipidemia, inadequate primary and secondary prevention efforts, complicated by a fragmented health system have been identified. Compelling evidence indicates that target LDL-C levels are not achieved throughout the Middle East region. In addition, high-risk patients are often left unidentified with adequate treatment. CONCLUSION: This statement recommends specific multilevel interventions to optimize the prevention, diagnosis, and treatment of ASCVD. These recommendations focus on strengthening primary and secondary prevention through education initiatives, establishment of specialized prevention and treatment centers, and development of local and regional CPGs.
format Online
Article
Text
id pubmed-7596183
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-75961832020-11-02 Improvement initiative in LDL-C management in Saudi Arabia: A call to action() Alasnag, Mirvat Awan, Zuhier Al Ghamdi, Ahmed Al Modaimeigh, Hind Al Shemiri, Mostafa Int J Cardiol Heart Vasc Review PURPOSE: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in the Saudi Arabia (KSA). Over the last decade dyslipidemia has been the predominant risk factor in KSA. The linear relationship between low density lipoprotein cholesterol (LDL-C) levels, a marker for dyslipidemia, and progression of ASCVD is well established. The objective of this paper is to to provide an overview of the burden of disease, outline current clinical practice guidelines (CPG), examine gaps in care, and provide actionable recommendations to prevent, diagnose, and treat dyslipidemia in KSA. RESULTS: Saudi Arabia has the highest prevalence of ASCVD in the Gulf region. Several gaps in the implementation of CPGs, including the underdiagnosis and undertreatment of dyslipidemia, inadequate primary and secondary prevention efforts, complicated by a fragmented health system have been identified. Compelling evidence indicates that target LDL-C levels are not achieved throughout the Middle East region. In addition, high-risk patients are often left unidentified with adequate treatment. CONCLUSION: This statement recommends specific multilevel interventions to optimize the prevention, diagnosis, and treatment of ASCVD. These recommendations focus on strengthening primary and secondary prevention through education initiatives, establishment of specialized prevention and treatment centers, and development of local and regional CPGs. Elsevier 2020-10-27 /pmc/articles/PMC7596183/ /pubmed/33145395 http://dx.doi.org/10.1016/j.ijcha.2020.100667 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Alasnag, Mirvat
Awan, Zuhier
Al Ghamdi, Ahmed
Al Modaimeigh, Hind
Al Shemiri, Mostafa
Improvement initiative in LDL-C management in Saudi Arabia: A call to action()
title Improvement initiative in LDL-C management in Saudi Arabia: A call to action()
title_full Improvement initiative in LDL-C management in Saudi Arabia: A call to action()
title_fullStr Improvement initiative in LDL-C management in Saudi Arabia: A call to action()
title_full_unstemmed Improvement initiative in LDL-C management in Saudi Arabia: A call to action()
title_short Improvement initiative in LDL-C management in Saudi Arabia: A call to action()
title_sort improvement initiative in ldl-c management in saudi arabia: a call to action()
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596183/
https://www.ncbi.nlm.nih.gov/pubmed/33145395
http://dx.doi.org/10.1016/j.ijcha.2020.100667
work_keys_str_mv AT alasnagmirvat improvementinitiativeinldlcmanagementinsaudiarabiaacalltoaction
AT awanzuhier improvementinitiativeinldlcmanagementinsaudiarabiaacalltoaction
AT alghamdiahmed improvementinitiativeinldlcmanagementinsaudiarabiaacalltoaction
AT almodaimeighhind improvementinitiativeinldlcmanagementinsaudiarabiaacalltoaction
AT alshemirimostafa improvementinitiativeinldlcmanagementinsaudiarabiaacalltoaction